Core Viewpoint - Baolite (300246) has recently attracted attention due to its announcement of expected losses for 2025 and the volatility in its stock price [1] Group 1: Performance and Operating Conditions - Baolite announced on February 11, 2026, that it expects a net profit loss attributable to shareholders of 60 million to 80 million yuan for 2025, which represents a narrowing of losses compared to the same period last year [2] - The primary reasons for the losses include market competition leading to price declines, rising raw material costs affecting gross margins, foreign exchange losses from the US dollar, and expenses related to convertible bond amortization [2] - The company indicated that cost control and efficiency measures have led to a year-on-year reduction in expenses, although asset impairment provisions have exerted some pressure on net profit [2] Group 2: Recent Stock Performance - Baolite's stock has shown significant volatility recently, with a cumulative decline of 0.74% over the last five trading days and a price fluctuation range of 15.66% [3] - In terms of capital flow, on February 12, there was a net outflow of 3.0371 million yuan from main funds, accounting for 2.14% of the total trading volume, while speculative funds saw a net inflow of 5.0501 million yuan [3] - The trading activity has been high, with a single-day turnover rate exceeding 9% on February 10, indicating increased market divergence [3] - Technically, the stock price is currently near the middle band of the Bollinger Bands, with a 20-day resistance level at 14.63 yuan and a support level at 12.35 yuan, while the MACD indicator shows weakness [3]

证券代码：300246 证券简称：宝莱特 公告编号：2026-005 关于预计触发可转债转股价格向下修正条件的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、证券代码：300246，证券简称：宝莱特 2、债券代码：123065，债券简称：宝莱转债 3、转股价格：23.97 元/股 4、转股期限：2021 年 3 月 11 日至 2026 年 9 月 3 日 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 根据《广东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》（以下简称"《募集说明书》"）规定：在本次发行的可转 换公司债券存续期间，当公司股票在任意连续三十个交易日中至少有十五个交易 日的收盘价低于当期转股价格的90%时，公司董事会有权提出转股价格向下修正 方案并提交公司股东会表决。 2026年1月30日至2026年2月12日，公司股票已有10个交易日的收盘价格低于 当期转股价格（23.97元/股）的90%，预计可能触发"宝莱转债"转股价格向下修 正条件。若触发转股价格向下修正条款 ...

Financial Performance - Guangdong Baolite Medical Technology Co., Ltd. (宝莱特) expects a net loss of 60 million to 80 million yuan for 2025, compared to a loss of 71.44 million yuan in the previous year[2]. - The net profit after deducting non-recurring gains and losses is projected to be a loss of 68 million to 95 million yuan, down from a loss of 96.54 million yuan last year[2]. Reasons for Losses - The primary reasons for the expected losses include a decline in gross margin due to competitive pricing pressures, inventory and equipment impairments, and foreign exchange losses[3]. - The company is facing significant risks from ongoing medical procurement policies and price reductions in its product categories[3]. Cash Flow and Financial Health - The company reported a net cash inflow from operating activities of 38 million yuan for the first nine months of 2025, with cash reserves of 648 million yuan as of September 2025, effectively covering short-term debts[4]. - The company's financial condition is assessed as weak, with a leverage score of 6/9 and liquidity score of 6/7[6]. Business Operations - The new production line of the subsidiary Suzhou Junkang Medical Technology Co., Ltd. has commenced operations, but there are uncertainties regarding order volume and capacity absorption[4]. Credit Rating and Outlook - The company's credit rating remains at AA- with a negative outlook, reflecting ongoing challenges in the blood purification market and competitive pressures[4]. - The rating agency will continue to monitor the competitive landscape and its impact on the company's credit rating and outlook[4]. Overall Business Situation - The overall business situation is rated at 5/7, indicating moderate performance in the current market environment[6].

Market Overview - The medical device sector increased by 0.9% on February 4, with SAIKOSHI leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Top Performers - SAIKOSHI (688338) closed at 32.11, up 10.15% with a trading volume of 63,600 shares and a transaction value of 197 million [1] - SHUOSHI BIO (6638889) closed at 71.46, up 5.69% with a trading volume of 15,900 shares and a transaction value of 113 million [1] - BAOLAIT (300246) closed at 13.51, up 2.74% with a trading volume of 166,100 shares and a transaction value of 224 million [1] Underperformers - KANGZHONG MEDICAL (688607) closed at 57.80, down 4.26% with a trading volume of 46,300 shares [2] - SINO MEDICAL (688108) closed at 22.70, down 3.77% with a trading volume of 170,600 shares and a transaction value of 387 million [2] - SANYOU MEDICAL (688085) closed at 21.05, down 3.08% with a trading volume of 39,800 shares and a transaction value of 84 million [2] Capital Flow - The medical device sector experienced a net outflow of 132 million from institutional investors, while retail investors saw a net outflow of 191 million [2] - Speculative funds had a net inflow of 323 million into the sector [2] Individual Stock Capital Flow - MAIRUI MEDICAL (300760) had a net inflow of 86.91 million from institutional investors, while retail investors had a net outflow of 169 million [3] - LIANSHENG MEDICAL (688271) saw a net inflow of 44.32 million from institutional investors, with a net outflow of 76.86 million from retail investors [3] - HUAKANG CLEAN (301235) had a net inflow of 31.25 million from institutional investors, while retail investors experienced a net outflow of 52.92 million [3]

Core Viewpoint - The medical device sector experienced a rise of 1.42% on February 3, with Huakang Clean leading the gains, while the overall market indices also showed positive performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4067.74, up by 1.29% [1]. - The Shenzhen Component Index closed at 14127.1, up by 2.19% [1]. Group 2: Top Gainers in Medical Device Sector - Huakang Clean (301235) closed at 53.83, with a gain of 9.86% and a trading volume of 114,200 shares, amounting to a transaction value of 610 million yuan [1]. - Baocait (300246) closed at 13.15, up by 7.96% with a trading volume of 178,500 shares, totaling 229 million yuan [1]. - Yirui Technology (688301) closed at 119.24, increasing by 7.10% with a trading volume of 41,000 shares, resulting in a transaction value of 477 million yuan [1]. - Hualan Co. (301093) closed at 86.08, up by 6.45% with a trading volume of 60,900 shares, totaling 482 million yuan [1]. - Tianzhihang (688277) closed at 24.18, increasing by 6.10% with a trading volume of 159,300 shares, amounting to 379 million yuan [1]. Group 3: Market Outflows and Inflows - The medical device sector saw a net outflow of 253 million yuan from institutional investors and a net outflow of 112 million yuan from speculative funds, while retail investors had a net inflow of 365 million yuan [2]. - The detailed fund flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3].

Group 1 - The company Baolite announced an expected net profit attributable to shareholders for 2025 ranging from -80 million to -60 million yuan, compared to -71.44 million yuan in the same period last year [2]

Core Viewpoint - The company is engaged in the research, production, sales, and service of medical device products, focusing on life information and support as well as nephrology medical sectors, with an expected net loss but a narrowing of losses compared to the previous year [5] Group 1: Financial Performance - The company anticipates a continued net loss during the reporting period, although the loss margin is expected to be smaller than the same period last year [5] - Revenue is projected to show slight growth, driven by enhanced management and operational efficiency [5] - The primary reason for the inability to achieve profitability is a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [5] Group 2: Cost Management and Impacts - The company is actively pursuing cost control and efficiency improvements, resulting in a year-on-year reduction in various expenses [5] - However, foreign exchange losses due to the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impact net profit [5] - The company has made provisions for asset impairment on inventory and certain production equipment based on prudence principles, which will affect the current net profit [5] Group 3: Future Projections - For 2025, the expected impact of non-recurring gains and losses on net profit is approximately 8.07 million yuan, primarily from government subsidies [5]

Core Viewpoint - Baolite expects a net profit attributable to shareholders of the listed company to be between -60 million and -80 million yuan for the year 2025, indicating continued losses but a narrowing of the loss compared to the previous year [1] Financial Performance - The company anticipates a net profit excluding non-recurring gains and losses to be between -95 million and -68 million yuan for 2025 [1] - Despite an increase in operating income, the company still expects to report a net loss due to various factors [1] Reasons for Losses - The primary reasons for the continued losses include: 1. Increased sales volume of most products, but a decline in sales prices due to market competition, coupled with rising raw material costs, leading to a decrease in overall gross margin [1] 2. Although the company has reduced various expenses, foreign exchange losses from the depreciation of the US dollar against the Chinese yuan and high amortization costs related to convertible bonds significantly impacted net profit [1] 3. The company has made provisions for asset impairment on inventory and certain production equipment based on the cautious principle of accounting standards due to declining product sales prices, which affected the current net profit [1] 4. Non-recurring gains and losses are expected to impact net profit by approximately 8.07 million yuan, primarily from government subsidies [1]

Financial Performance Expectations - The company expects a net profit in the range of -80 million to -60 million CNY for the year 2025, indicating a decrease of 11.98% to an increase of 16.01% compared to the previous year[2][3]. - The expected net profit after deducting non-recurring losses is projected to be between -95 million and -68 million CNY, with a growth rate of 1.59% to 29.56% year-on-year[3]. - The company anticipates a non-recurring gain of approximately 8.07 million CNY, primarily from government subsidies, impacting the net profit positively[6]. Cost Management and Profitability - Despite an increase in product sales volume, the overall gross margin has declined due to competitive pricing pressures and rising raw material costs[5]. - The company has implemented cost control measures, resulting in a reduction of various expenses year-on-year, although foreign exchange losses and high amortization costs related to convertible bonds have negatively affected net profit[5]. - The company has made provisions for asset impairment on inventory and certain production equipment due to declining product sales prices, which will impact the net profit for the period[6]. Communication and Reporting - The company has communicated with the auditing firm regarding the performance forecast, and there are no discrepancies noted[4]. - The specific financial data for the 2025 fiscal year will be disclosed in the annual report, and any significant discrepancies will be reported in accordance with disclosure regulations[7].

Market Overview - The medical device sector experienced a slight decline of 0.08% on January 22, with Aisheren leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Top Performers - Baolait (300246) saw a significant increase of 11.93%, closing at 14.64 with a trading volume of 374,600 shares and a transaction value of 530 million [1] - Aojing Medical (688613) rose by 3.65%, closing at 24.12 with a trading volume of 56,300 shares and a transaction value of 134 million [1] - Adit (301580) increased by 3.64%, closing at 53.79 with a trading volume of 42,100 shares and a transaction value of 222 million [1] Underperformers - Aisheren (920050) experienced the largest decline of 12.17%, closing at 38.68 with a trading volume of 86,600 shares and a transaction value of 341 million [2] - Shuoshi Bio (688399) fell by 6.39%, closing at 79.42 with a trading volume of 46,300 shares and a transaction value of 374 million [2] - Tianchen Medical (688013) decreased by 3.78%, closing at 44.25 with a trading volume of 25,900 shares and a transaction value of 114 million [2] Capital Flow - The medical device sector saw a net outflow of 332 million from institutional investors, while retail investors contributed a net inflow of 152 million [2] - The top stocks by net inflow from retail investors included Guanhao Bio (300238) with a net inflow of 16.41 million [3] - Institutional investors showed a strong net inflow in Lianying Medical (688271) with 63.88 million, while retail investors had a net outflow of 68.63 million [3]